Pulmotech MAA kit for the preparation of technetium Tc 99m albumin aggregated 2 mg/15mL Injection, Powder, Lyophilized, For Suspension — NDC 69945-139-20 (Billing 69945-0139-20)
This is a package of Pulmotech MAA kit for the preparation of technetium Tc 99m albumin aggregated 2 mg/15mL Injection, Powder, Lyophilized, For Suspension from Curium US LLC, marketed since Mar 2020 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 69945-139-20 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 69945 labeler · 139 product · 20 package
- Package marketed since
- Mar 20, 2020
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6994513920 7
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 080953
- GCN: 47943
- HICL (First Databank): 024536
- AHFS class code: 36:68.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 69945-0139-20 You're viewing this Main listing | 5 VIAL, MULTI-DOSE in 1 CELLO PACK / 15 mL in 1 VIAL, MULTI-DOSE | 2020-03-20 | — | Active |
| 69945-0139-40 69945-139-40 | 30 VIAL, MULTI-DOSE in 1 CARTON / 15 mL in 1 VIAL, MULTI-DOSE | 2020-03-20 | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Pulmotech MAA kit for the preparation of technetium Tc 99m albumin aggregated 2 mg/15mL Injection, Powder, Lyophilized, For Suspension?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Pulmotech MAA 2 mg/15mLthis 69945-0139-20 | Curium | 5 vials | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Purple Book · refreshed Sep 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Mar 20, 2032 |
Is there a biosimilar for PULMOTECH MAA PREPARATION KIT?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Sep 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Curium US LLC labeler code 69945
- Technescan PYP Technetium Tc 99m Pyrophosphate 11.9 mg/10mL; 3.2 mg/10mL Injection, Powder, Lyophilized, For Solution NDC 69945-094-20
- Technescan MAG3 Technescan Tc 99m Mertiatide 1 mg Injection, Powder, Lyophilized, For Solution NDC 69945-096-20
- Xenon, Xe-133 5 mCi/mL Gas NDC 69945-097-11
- Xenon, Xe-133 10 mCi/mL Gas NDC 69945-098-21
- Ultra-Technekow V4 Technetium Tc-99m 11 Ci Injection, Solution NDC 69945-110-12
- THALLOUS CHLORIDE Tl 201 1 mCi/mL Injection, Solution NDC 69945-120-28
- Ultra-Technekow V4 Technetium Tc-99m 14 Ci Injection, Solution NDC 69945-140-13
- Ultra-Technekow V4 Technetium Tc-99m 16 Ci Injection, Solution NDC 69945-160-14
- Ioflupane I 123 2 mCi/mL Injection, Solution NDC 69945-166-05
- BEXLUTRY LUTETIUM OXODOTREOTIDE LU-177 10 mCi/mL Injection NDC 69945-177-01
- GALLIUM CITRATE GA-67 2 mCi/mL Injection, Solution NDC 69945-180-06
- Ultra-Technekow V4 Technetium Tc-99m 19 Ci Injection, Solution NDC 69945-190-15
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE PULMOTECH MAA, after radiolabeling with technetium-99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults. PULMOTECH MAA, after radiolabeling with technetium-99m is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
( 1 ) Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For lung perfusion scintigraphy, the following recommended activity is administered by intravenous injection. • Adults : 37 MBq to 148 MBq (1 mCi to 4 mCi) and 200,000 particles to 700,000 particles. ( 2.3 ) • Pediatric patients aged 4 weeks and older : 0.925 MBq/kg to
1.85MBq/kg of body weight (0.025 mCi/kg to 0.05 mCi/kg); the minimum activity is
7.4MBq (0.2 mCi). The number of particles will vary with age and body weight of the pediatric patient. ( 2.3 ) • Pediatric patients aged less than 4 weeks :
7.4 MBq to
18.5MBq (0.2 mCi to 0.5 mCi); 10,000 particles to 50,000 particles. ( 2.3 ) For peritoneovenous shunts scintigraphy in adults: 37 MBq to 111 MBq (1 mCi to 3 mCi) and 200,000 particles to 700,000 particles by intraperitoneal injection. ( 2.4 ) See Full Prescribing Information for radiation safety, patient preparation, drug preparation, administration, imaging, and radiation dosimetry information. ( 2.1 , 2.2 , 2.5 , 2.6 , 2.7 )
2.1Radiation Safety – Drug Handling After radiolabeling of PULMOTECH MAA, the vial contains Technetium Tc 99m Albumin Aggregated Injection. Handle Technetium Tc 99m Albumin Aggregated Injection with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions ( 5.4 )] . Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Albumin Aggregated Injection.
Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
2.2Patient Preparation Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Technetium Tc 99m Albumin Aggregated Injection and to continue to drink and void frequently following administration to reduce radiation exposure [see Warnings and Precautions ( 5.4 )] . 2. 3 Recommended Dosage for Lung Perfusion Scintigraphy Adult Patients The recommended activity for lung perfusion scintigraphy in adult patients is 37 MBq to 148 MBq (1 mCi to 4 mCi) by intravenous injection.
The range of particle numbers per single injection should be 200,000 to 700,000 with the recommended number of approximately 350,000. Depending on the activity added and volume of the final radiolabeled product, the volume of the dose may vary from 0.2 mL to 1.9 mL. The number of particles available per dose of Technetium Tc 99m Albumin Aggregated Injection will vary depending on the physical decay of technetium-99m that has occurred.
The number of particles in any dose and volume to be administrated may be calculated as follows: Where: V a = volume to be administered in mL D = desired activity to be administered in MBq (mCi) C = concentration at calibration time of Sodium Pertechnetate Tc 99m Injection to be added to the reaction vial in MBq/mL (mCi/mL) Fr = fraction of Technetium-99m remaining after the time of calibration from Table 6 [see Description ( 11.3 )] P = number of particles in dose to be administered V a = volume to be administered in mL V Tc = volume of Sodium Pertechnetate Tc 99m Injection added to reaction vial in mL N = number of particles per vial.
The number of particles per vial for the lot is located on the vial label. Pediatric Patients Aged 4 Weeks and Older The recommended activity for lung perfusion scintigraphy in pediatric patients aged 4 weeks and older by intravenous injection is based on body weight and ranges from 0.925 MBq/kg to
1.85MBq/kg (0.025 mCi/kg to 0.05 mCi/kg). The minimum recommended dose for lung perfusion scintigraphy in this age is
7.4MBq (0.2 mCi). The number of particles will vary with age and body weight of the pediatric patient. Particle numbers administered in four different age and weight categories are shown in… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Kit for the preparation of Technetium Tc 99m Albumin Aggregated Injection: 2 mg of albumin aggregated as a non-radioactive, white lyophilized powder in a multiple-dose reaction vial for radiolabeling with Sodium Pertechnetate Tc 99m Injection to prepare a suspension of Technetium Tc 99m Albumin Aggregated Injection containing up to
6.85MBq (185 mCi) in 2 to 13 mL volume at time of preparation. Each vial contains 2,000,000 to 4,000,000 particles. Kit for the preparation of Technetium Tc 99m Albumin Aggregated Injection: 2 mg of albumin aggregated as a lyophilized powder in a multiple-dose reaction vial. Upon radiolabeling, it provides a suspension of Technetium Tc 99m Albumin Aggregated Injection containing up to
6.85MBq (185 mCi) in 2 to 13 mL volume at time of preparation. Each vial contains 2,000,000 to 4,000,000 particles. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS PULMOTECH MAA is contraindicated in patients with: Severe pulmonary hypertension [see Warnings and Precautions ( 5.1 ) ]. A history of hypersensitivity to albumin human. Reactions have included anaphylaxis [see Warnings and Precautions ( 5.2 )]. Severe pulmonary hypertension. ( 4 ) A history of hypersensitivity reactions to albumin human. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Patients with P ulmonary H ypertension : Administer the lowest number of particles possible and have emergency resuscitation equipment available. ( 5.1 ) Hypersensitivity Reactions : Have emergency resuscitation equipment and trained personnel available. Interrupt the administration if a reaction occurs during administration.
Monitor patients. ( 5.2 ) Risk of Temporary Impediment to Blood Flow in Patients with Right-to-Left Heart Shunts : Administer the lowest possible number of particles. ( 5.3 ) Radiation Risks : Ensure safe handling to minimize radiation exposure to the patient and healthcare providers.
( 5.4 )
5.1Patients with Pulmonary Hypertension Deaths have been reported in patients with severe pulmonary hypertension after the administration of technetium Tc 99m albumin aggregated products [see Adverse Reactions ( 6 )] . Assess patients for history or signs of pulmonary hypertension. PULMOTECH MAA is contraindicated in patients with severe pulmonary hypertension [see Contraindications ( 4 )] .
Administer the lowest number of particles possible, have emergency resuscitation equipment available, and monitor patients for adverse reactions .
5.2Hypersensitivity Reactions Serious hypersensitivity reactions including anaphylaxis have been reported in patients treated with products containing albumin human, including PULMOTECH MAA [see Adverse Reactions ( 6 )] . Obtain a history of allergy or hypersensitivity reactions. PULMOTECH MAA is contraindicated in patients with a history of hypersensitivity to albumin human [see Contraindications ( 4 )] .
Have emergency resuscitation equipment and trained personnel available prior to administration of Technetium Tc 99m Albumin Aggregated Injection. Monitor all patients for hypersensitivity reactions.
5.3Risk of Temporary Impediment to Blood Flow in Patients with Right-to-Left Heart Shunts In patients with right-to-left heart shunts, risk for temporary mechanical impediment to blood flow may exist due to the rapid entry of aggregated albumin into the systemic circulation. Administer the lowest possible number of particles of Technetium Tc 99m Albumin Aggregated Injection in these patients.
5.4Radiation Risks Technetium Tc 99m albumin aggregated contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration ( 2.2 )] .
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Patients with Pulmonary Hypertension [ see Warnings and Precautions ( 5.1 ) ] . Hypersensitivity Reactions [ see Warnings and Precautions ( 5.2 ) ] . The following adverse reactions associated with the use of technetium Tc 99m albumin aggregated products including PULMOTECH MAA have been identified in clinical studies or postmarketing reports.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular Disorders : Deaths in patients with severe pulmonary hypertension Immune System Disorders : Hypersensitivity reactions such as anaphylaxis, impairment of cardiac and circulatory functions in the form of changes in respiration, pulse, and blood pressure, chest pain, and syncope, urticaria, reddening of the face, sweating, and nausea Skin and Subcutaneous Tissue Disorders : Injection site reactions The following adverse reactions have been reported: Death in patients with severe pulmonary hypertension, anaphylaxis, impairment of cardiac and circulatory functions in the form of changes in respiration, pulse, and blood pressure, chest pain, and possible syncope, urticaria, reddening of the face, sweating, nausea, and injection site reaction.
( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact CURIUM US LLC at 1-866-789-2211 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Lactation: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 24 hours after technetium Tc 99m albumin aggregated injection administration. ( 8.2 )
8.1Pregnancy Risk Summary Available data from case reports on Technetium Tc 99m Albumin Aggregated Injection use are insufficient to evaluate drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies with technetium Tc 99m albumin aggregated have not been conducted. Although all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose, the radiation exposure to the fetus from technetium Tc 99m albumin aggregated is expected to be low (less than 0.50 mGy) (see Data) .
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Human Data No adverse fetal effects of radiation risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 10 mGy fetal doses.
8.2Lactation Risk Summary Technetium-99m is present in breast milk. There are no data on the effects of technetium Tc 99m albumin aggregated on the breastfed infant or the effects on milk production. PULMOTECH MAA is used for imaging in infants with lung disease; exposure to technetium-99m via breastmilk is expected to be lower.
Based on clinical guidelines, exposure of technetium Tc 99m albumin aggregated to a breastfed infant may be minimized by advising a lactating woman to temporarily discontinue breastfeeding and to pump and discard breast milk for a minimum of at least 24 hours after administration of Technetium Tc 99m Albumin Aggregated Injection. The developmental and health benefits of breastfeeding should be considered along with a mother’s clinical need for PULMOTECH MAA, any potential adverse effects on the breastfed child from technetium Tc 99m albumin aggregated or from the underlying maternal condition.
8.4Pediatric Use PULMOTECH MAA, after radiolabeling with technetium Tc-99m, is indicated for lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in pediatric patients (birth to less than 17 years of age). The safety profile of Technetium Tc99m Albumin Aggregated Injection is similar to the one in adults. The safety and efficacy of PULMOTECH MAA have not been established for peritoneovenous shunt scintigraphy in pediatric patients.
8.5Geriatric Use No formal studies of PULMOTECH MAA in subjects aged 65 and over were performed to determine whether they respond differently from younger adult subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients. In general, dose selection for an elderly patient should be cautious; administering the low end of the particle dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary Available data from case reports on Technetium Tc 99m Albumin Aggregated Injection use are insufficient to evaluate drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies with technetium Tc 99m albumin aggregated have not been conducted. Although all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose, the radiation exposure to the fetus from technetium Tc 99m albumin aggregated is expected to be low (less than 0.50 mGy) (see Data) .
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Human Data No adverse fetal effects of radiation risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 10 mGy fetal doses.
🧒 Pediatric Use ▾
8.4Pediatric Use PULMOTECH MAA, after radiolabeling with technetium Tc-99m, is indicated for lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in pediatric patients (birth to less than 17 years of age). The safety profile of Technetium Tc99m Albumin Aggregated Injection is similar to the one in adults. The safety and efficacy of PULMOTECH MAA have not been established for peritoneovenous shunt scintigraphy in pediatric patients.
🧓 Geriatric Use ▾
8.5Geriatric Use No formal studies of PULMOTECH MAA in subjects aged 65 and over were performed to determine whether they respond differently from younger adult subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients. In general, dose selection for an elderly patient should be cautious; administering the low end of the particle dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Within 1 to 5 minutes of intravenous injection, over 90 percent of the technetium Tc 99m albumin aggregated particles are trapped in the arterioles and capillaries of the lung. Following intraperitoneal administration, technetium Tc 99m albumin aggregated mixes with the peritoneal fluid. Clearance from the peritoneal cavity varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent.
12.2Pharm a codynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of technetium Tc 99m albumin aggregated have not been fully characterized.
12.3Pharmacokinetics Distribution Organ selectivity is a direct result of particle size. At 10 micrometer and below, the albumin aggregates are taken up by the reticuloendothelial system. Above 10 to 15 micrometer, the aggregates become lodged in the lung capillaries by a purely mechanical process.
Distribution of aggregated albumin in the lungs is a function of regional pulmonary blood flow. The albumin aggregated is sufficiently fragile for the capillary micro-occlusion to be temporary. Erosion and fragmentation reduce the particle size, allowing passage of the aggregates through the pulmonary alveolar capillary bed.
The fragments then accumulate in the reticuloendothelial system. Elimination Elimination of the technetium Tc 99m albumin aggregated particles from the normal and abnormal human lungs occurs with a biological half-life of 10.8 hours (range 6.9 to 19 hours, n=5).
🧬 Mechanism of Action ▾
12.1Mechanism of Action Within 1 to 5 minutes of intravenous injection, over 90 percent of the technetium Tc 99m albumin aggregated particles are trapped in the arterioles and capillaries of the lung. Following intraperitoneal administration, technetium Tc 99m albumin aggregated mixes with the peritoneal fluid. Clearance from the peritoneal cavity varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied PULMOTECH MAA (kit for the preparation of technetium Tc 99m albumin aggregated) injection contains 2 mg of albumin aggregated as a white lyophilized powder in a multiple-dose reaction vial, sealed under an atmosphere of nitrogen, for radiolabeling with Sodium Pertechnetate Tc 99m Injection to prepare Technetium Tc 99m Albumin Aggregated Injection. PULMOTECH MAA is supplied as: a carton (clam shell) of 5 vials (NDC 69945-139-20) a carton of 30 vials (NDC 69945-139-40) Each 5-vial carton contains 5 multiple-dose reaction vials and 5 radioassay information labels.
Each 30-vial carton contains 30 multiple-dose reaction vials and 30 radioassay information labels. Storage and Handling Before radiolabeling, store supplied reaction vials at 2°C to 25°C (36°F to 77ºF). After radiolabeling with Sodium Pertechnetate Tc 99m Injection, store Technetium Tc 99m Albumin Aggregated Injection in a lead vial shield with cap in place, refrigerated at 2°C to 8°C (36°F to 46ºF) when not in use.
Use within 18 hours after radiolabeling [ see Dosage and Administration ( 2.5 )] . Dispose unused Technetium Tc 99m Albumin Aggregated Injection in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide. This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.
📋 Description ▾
11 DESCRIPTION
11.1Product Characteristics PULMOTECH MAA contains albumin aggregated obtained by fractionating material (source blood, plasma, serum, or placentas) from healthy human donors. The macroaggregated albumin (MAA) particles are formed by heat denaturation of stannous chloride treated albumin human under controlled conditions. Each vial contains 2,000,000 to 4,000,000 particles.
The particle size distribution of the aggregated albumin is such that not less than 90% are 10 to 90 micrometers in size. There are no aggregated albumin particles greater than 150 micrometers in size as determined by circular equivalents. PULMOTECH MAA (kit for the preparation of technetium Tc 99m albumin aggregated) injection provides a sterile, non-pyrogenic, non-radioactive, white lyophilized powder in a multiple-dose reaction vial, sealed under an atmosphere of nitrogen, for radiolabeling with Sodium Pertechnetate Tc 99m Injection to prepare Technetium Tc 99m Albumin Aggregated Injection, a radioactive diagnostic agent, for intravenous or intraperitoneal use.
Each reaction vial contains 2 mg of albumin aggregated, albumin human (7.1 mg), stannous chloride (0.1 mg minimum; 0.22 mg maximum stannous and stannic), sodium chloride (9 mg). Hydrochloric acid may have been added for pH adjustment. The pH is between 5 and 7.
It contains no preservatives.
11.2Physical Characteristics Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging is listed in Table 4. Table 4 – Principal Radiation Emission Data for Technetium-99m Radiation Mean % per Disintegration Energy (keV) Gamma-2 89.07 140.5
11.3 External Radiation The specific gamma ray constant for technetium-99m is
0.78R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) for technetium-99m is 0.017 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 5.
For example, the use of 0.25 cm of Pb will decrease the external radiation exposure by a factor of about 1,000. Table 5 – Radiation Attenuation by Lead Shielding Shield Thickness(Pb) cm Coefficient of Attenuation 0.017 0.5 0.08 10 -1 0.16 10 -2 0.25 10 -3 0.33 10 -4 To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 6. Table 6– Physical Decay Chart for Technetium-99m, Half-Life
6.02Hours Hours Fraction Remaining Hours Fraction Remaining 0* 1.000 7 0.447 1 0.891 8 0.398 2 0.794 9 0.355 3 0.708 10 0.316 4 0.631 11 0.282 5 0.562 12 0.251 6 0.501 *Calibration Time
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Adequate Hydration Advise patients to drink a sufficient amount of water to ensure adequate hydration before their study and urge them to drink and urinate as often as possible during the first hours following the administration of Technetium Tc 99m Albumin Aggregated Injection in order to reduce radiation exposure [see Dosage and Administration ( 2.2 )] . Pregnancy Advise pregnant women of the risk of fetal exposure to radiation doses if they undergo a radionucleotide procedure [see Use in Specific Populations ( 8.1 )].
Lactation Advise a lactating woman to temporally discontinue breastfeeding and to pump and discard breast milk for 24 hours after Technetium Tc 99m Albumin Aggregated Injection administration to minimize radiation exposure to a breastfed infant [see Use in Specific Populations ( 8.2 )]. Manufactured by: CIS bio International Route Departementale 306 Gif-sur-Yvette, Ile-de-France 91190, France U.S License No. 2204 Distributed by: Curium US LLC 2703 Wagner Place Maryland Heights, MO 63043 ©2025 Curium US LLC.
Pulmotech™, Curium™, and the Curium logo are trademarks of a Curium company. A139I0 Curium™
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Distribution Organ selectivity is a direct result of particle size. At 10 micrometer and below, the albumin aggregates are taken up by the reticuloendothelial system. Above 10 to 15 micrometer, the aggregates become lodged in the lung capillaries by a purely mechanical process.
Distribution of aggregated albumin in the lungs is a function of regional pulmonary blood flow. The albumin aggregated is sufficiently fragile for the capillary micro-occlusion to be temporary. Erosion and fragmentation reduce the particle size, allowing passage of the aggregates through the pulmonary alveolar capillary bed.
The fragments then accumulate in the reticuloendothelial system. Elimination Elimination of the technetium Tc 99m albumin aggregated particles from the normal and abnormal human lungs occurs with a biological half-life of 10.8 hours (range 6.9 to 19 hours, n=5).
🧬 Pharmacodynamics ▾
12.2Pharm a codynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of technetium Tc 99m albumin aggregated have not been fully characterized.
🧪 Nonclinical Toxicology ▾
1 3 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium Tc 99m albumin aggregated affects fertility in males or females.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium Tc 99m albumin aggregated affects fertility in males or females.
📄 Recent Major Changes ▾
Dosage and Administration, Directions for Drug Preparation and Handling ( 2.5 ) 10/2025
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL Kit for the Preparation of Technetium Tc 99m Albumin Aggregated NDC 69945-139-10 Pulmotech™ MAA Sterile, Multiple-Dose Vial Rx only Injection For Intravenous or Intraperitoneal use after radiolabeling with Sodium Pertechnetate Tc 99m Injection. Each reaction vial contains 2 mg of albumin aggregated. STORAGE: Before radiolabeling , store at 2°C to 25°C (36°F to 77°F).
After radiolabeling , store vial in a suitable lead shield in a refrigerator at 2°C to 8°C (36°F to 46°F). Use within 18 hours after radiolabeling. Recommended Dosage: See prescribing information.
Manufactured by: CIS bio International, Gif-sur-Yvette Ile-de-France 91190, France U.S. License No. 2204 Distributed by: Curium US LLC, Maryland Heights, MO 63043 A139V0 R08/2023 image description
PRINCIPAL DISPLAY PANEL NDC 69945-139-40 Kit for the Preparation of Technetium Tc 99m Albumin Aggregated Pulmotech™ MAA Injection For Intravenous or Intraperitoneal use after radiolabeling with Sodium Pertechnetate Tc 99m Injection. Rx only STORAGE: Before radiolabeling, store at 2°C to 25°C (36°F to 77°F). After radiolabeling, store vial in a suitable lead shield in a refrigerator at 2°C to 8°C (36°F to 46°F).
Use within 18 hours after radiolabeling. CURIUM™ 30 Multiple-Dose Vials PINCH AT CORNERS / PULL OUT Recommended Dosage: See prescribing information. CARTON CONTAINS: 30 sterile, multiple-dose reaction vials 30 radioassay information labels 1 Prescribing Information Each reaction vial contains 2 mg of albumin aggregated, albumin human (7.1 mg), stannous chloride (0.1 mg minimum; 0.22 mg maximum stannous and stannic), and sodium chloride (9 mg).
Hydrochloric acid has been used for pH adjustment; Sealed under nitrogen; Contains no preservative. Manufactured by: CIS bio International Route Departementale 306 Gif-sur-Yvette Ile-de-France 91190, France U.S. License No.
2204 Distributed by: Curium US LLC 2703 Wagner Place Maryland Heights, MO 63043 Convenient Reorder Point Maximum Six Vials Remaining Open Flap For Prescribing Information and Radioassay Information Labels A139DK R08/2023 image description
Medicaid utilization by pack size
Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |